$RGEN News

3 Reasons RGEN is Risky and 1 Stock to Buy Instead

Benchmark Upgrades Repligen to Buy, Announces $185 Price Target

Evercore ISI Group Maintains Outperform on Repligen, Raises Price Target to $160

Is Repligen Corporation (RGEN) A Good Stock To Buy Now?

Repligen Corporation (RGEN) Dropped Following the Earnings Release

Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools

Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference Transcript

HSBC Maintains Buy on Repligen, Lowers Price Target to $150

Wolfe Research Assumes Repligen at Outperform, Announces Price Target of $145

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks

Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report

Why Repligen (RGEN) Stock Is Trading Up Today

3 Small-Cap Stocks We Steer Clear Of

RBC Capital Reinstates Outperform on Repligen, Announces $160 Price Target

5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Barclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN)